These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 37298588)

  • 21. miR-124 and Androgen Receptor Signaling Inhibitors Repress Prostate Cancer Growth by Downregulating Androgen Receptor Splice Variants, EZH2, and Src.
    Shi XB; Ma AH; Xue L; Li M; Nguyen HG; Yang JC; Tepper CG; Gandour-Edwards R; Evans CP; Kung HJ; deVere White RW
    Cancer Res; 2015 Dec; 75(24):5309-17. PubMed ID: 26573802
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biphasic transcriptional and posttranscriptional regulation of MYB by androgen signaling mediates its growth control in prostate cancer.
    Acharya S; Anand S; Khan MA; Zubair H; Srivastava SK; Singh S; Singh AP
    J Biol Chem; 2023 Jan; 299(1):102725. PubMed ID: 36410437
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HOXC8 inhibits androgen receptor signaling in human prostate cancer cells by inhibiting SRC-3 recruitment to direct androgen target genes.
    Axlund SD; Lambert JR; Nordeen SK
    Mol Cancer Res; 2010 Dec; 8(12):1643-55. PubMed ID: 21047772
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of evodiamine as a suppressor of prostate cancer progression by reducing AR transcriptional activity via targeting Src.
    Cheng P; Zhang X; Wang X; Liu C; Zhao X; Fan J; Xu C
    Endocrine; 2022 Feb; 75(2):635-645. PubMed ID: 34713388
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of treatment with androgen receptor ligands on microRNA expression of prostate cancer cells.
    Segal CV; Koufaris C; Powell C; Gooderham NJ
    Toxicology; 2015 Jul; 333():45-52. PubMed ID: 25846647
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MicroRNA-185 suppresses proliferation, invasion, migration, and tumorigenicity of human prostate cancer cells through targeting androgen receptor.
    Qu F; Cui X; Hong Y; Wang J; Li Y; Chen L; Liu Y; Gao Y; Xu D; Wang Q
    Mol Cell Biochem; 2013 May; 377(1-2):121-30. PubMed ID: 23417242
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epigallocatechin-3-gallate Enhances the Efficacy of MicroRNA-34a Mimic and MicroRNA-93 Inhibitor Co-transfection in Prostate Cancer Cell Line.
    Mokhtari H; Yaghmaei B; Sirati-Sabet M; Jafari N; Mardomi A; Abediankenari S; Mahrooz A
    Iran J Allergy Asthma Immunol; 2020 Dec; 19(6):612-623. PubMed ID: 33463130
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SIRT7 depletion inhibits cell proliferation and androgen-induced autophagy by suppressing the AR signaling in prostate cancer.
    Ding M; Jiang CY; Zhang Y; Zhao J; Han BM; Xia SJ
    J Exp Clin Cancer Res; 2020 Feb; 39(1):28. PubMed ID: 32019578
    [TBL] [Abstract][Full Text] [Related]  

  • 29. miR-137 Targets p160 Steroid Receptor Coactivators SRC1, SRC2, and SRC3 and Inhibits Cell Proliferation.
    Eedunuri VK; Rajapakshe K; Fiskus W; Geng C; Chew SA; Foley C; Shah SS; Shou J; Mohamed JS; Coarfa C; O'Malley BW; Mitsiades N
    Mol Endocrinol; 2015 Aug; 29(8):1170-83. PubMed ID: 26066330
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A transcriptional target of androgen receptor, miR-421 regulates proliferation and metabolism of prostate cancer cells.
    Meng D; Yang S; Wan X; Zhang Y; Huang W; Zhao P; Li T; Wang L; Huang Y; Li T; Li Y
    Int J Biochem Cell Biol; 2016 Apr; 73():30-40. PubMed ID: 26827675
    [TBL] [Abstract][Full Text] [Related]  

  • 31. miR-199a-3p targets stemness-related and mitogenic signaling pathways to suppress the expansion and tumorigenic capabilities of prostate cancer stem cells.
    Liu R; Liu C; Zhang D; Liu B; Chen X; Rycaj K; Jeter C; Calhoun-Davis T; Li Y; Yang T; Wang J; Tang DG
    Oncotarget; 2016 Aug; 7(35):56628-56642. PubMed ID: 27447749
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of microRNAs 371 and 34a in androgen receptor control influencing prostate cancer behavior.
    Leite KR; Morais DR; Florez MG; Reis ST; Iscaife A; Viana N; Moura CM; Silva IA; Katz BS; Pontes J; Nesrallah A; Srougi M
    Urol Oncol; 2015 Jun; 33(6):267.e15-22. PubMed ID: 25920548
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MiR-205-driven downregulation of cholesterol biosynthesis through SQLE-inhibition identifies therapeutic vulnerability in aggressive prostate cancer.
    Kalogirou C; Linxweiler J; Schmucker P; Snaebjornsson MT; Schmitz W; Wach S; Krebs M; Hartmann E; Puhr M; Müller A; Spahn M; Seitz AK; Frank T; Marouf H; Büchel G; Eckstein M; Kübler H; Eilers M; Saar M; Junker K; Röhrig F; Kneitz B; Rosenfeldt MT; Schulze A
    Nat Commun; 2021 Aug; 12(1):5066. PubMed ID: 34417456
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors.
    Mostaghel EA; Solomon KR; Pelton K; Freeman MR; Montgomery RB
    PLoS One; 2012; 7(1):e30062. PubMed ID: 22279565
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Src kinase potentiates androgen receptor transactivation function and invasion of androgen-independent prostate cancer C4-2 cells.
    Asim M; Siddiqui IA; Hafeez BB; Baniahmad A; Mukhtar H
    Oncogene; 2008 Jun; 27(25):3596-604. PubMed ID: 18223692
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoisoliquiritin exerts tumor suppressive effects on prostate cancer by repressing androgen receptor activity.
    Chen C; Shao R; Li B; Zhai Y; Wang T; Li X; Miao L; Huang J; Liu R; Liu E; Zhu Y; Gao X; Zhang H; Wang Y
    Phytomedicine; 2021 May; 85():153514. PubMed ID: 33676083
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of miR-133b and RB1CC1 as independent predictors for biochemical recurrence and potential therapeutic targets for prostate cancer.
    Li X; Wan X; Chen H; Yang S; Liu Y; Mo W; Meng D; Du W; Huang Y; Wu H; Wang J; Li T; Li Y
    Clin Cancer Res; 2014 May; 20(9):2312-25. PubMed ID: 24610824
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activation of the KDM5A/miRNA-495/YTHDF2/m6A-MOB3B axis facilitates prostate cancer progression.
    Du C; Lv C; Feng Y; Yu S
    J Exp Clin Cancer Res; 2020 Oct; 39(1):223. PubMed ID: 33087165
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multifaceted Function of MicroRNA-299-3p Fosters an Antitumor Environment Through Modulation of Androgen Receptor and VEGFA Signaling Pathways in Prostate Cancer.
    Ganapathy K; Staklinski S; Hasan MF; Ottman R; Andl T; Berglund AE; Park JY; Chakrabarti R
    Sci Rep; 2020 Mar; 10(1):5167. PubMed ID: 32198489
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MALAT1 knockdown inhibits prostate cancer progression by regulating miR-140/BIRC6 axis.
    Hao T; Wang Z; Yang J; Zhang Y; Shang Y; Sun J
    Biomed Pharmacother; 2020 Mar; 123():109666. PubMed ID: 31935634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.